Title:
FUSION PROTEIN COMPRISING TARGETING PEPTIDE OF CD13 AND LIDAMYCIN
Document Type and Number:
WIPO Patent Application WO/2008/145013
Kind Code:
A8
Abstract:
Provided is a fusion protein NGR-LDP-AE, which comprises targeting peptide of CD13, lidamycin apoprotein LDP and activated form enediyne chromophore AE combined with the LDP. This fusion protein can be used for targeted cancer therapy.
Inventors:
ZHENG YANBO (CN)
ZHEN YONGSU (CN)
SHANG BOYANG (CN)
LIU XIUJUN (CN)
WU SHUYING (CN)
ZHEN YONGSU (CN)
SHANG BOYANG (CN)
LIU XIUJUN (CN)
WU SHUYING (CN)
Application Number:
PCT/CN2008/001014
Publication Date:
July 30, 2009
Filing Date:
May 26, 2008
Export Citation:
Assignee:
INST MEDICINAL BIOTECHNOLOGY (CN)
ZHENG YANBO (CN)
ZHEN YONGSU (CN)
SHANG BOYANG (CN)
LIU XIUJUN (CN)
WU SHUYING (CN)
ZHENG YANBO (CN)
ZHEN YONGSU (CN)
SHANG BOYANG (CN)
LIU XIUJUN (CN)
WU SHUYING (CN)
International Classes:
C07K19/00; A61K38/16; A61P35/00; C12N1/21; C12N15/62; C12N15/63; C12P21/02
Attorney, Agent or Firm:
CCPIT PATENT & TRADEMARK LAW OFFICE (Vantone New World Plaza2 Fuchengmenwai Street, Beijing 7, CN)
Download PDF: